How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.
News|Articles|February 20, 2025
Social Media's Influence on Young Women's Reproductive Decisions
Author(s)Miranda Schmalfuhs
In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.
Advertisement
Advertisement
Mis- and disinformation on social media is a growing concern for both pharmaceutical companies and patients alike. Distrust in the various different platforms leave patients looking for guidance from any "trusted source," regulated or not, and the consequences could be disastrous. Young adults are increasing looking to their online parasocial relationships for advice on many topics, including health and medical care. This is just one of many challenges that the spread of misinformation presents.
Related to this article
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Advertisement
Advertisement